Evaluating an OX40 ligand-blocking antibody for eczema treatment in the STREAM-AD clinical trial: a plain language summary

This Plain Language Summary of Publication article (PLSP) from Immunotherapy describes the STREAM-AD clinical study that evaluated amlitelimab, an investigational injectable anti-OX40 ligand antibody, for treating moderate-to-severe atopic dermatitis (eczema). The research assessed both efficacy and safety of this novel treatment approach in patients who didn’t respond adequately to topical medications. Unlike existing therapies, amlitelimab targets a specific immune pathway (OX40 ligand) and was compared to placebo. The study also examined how long symptom relief persisted after treatment discontinuation.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis’ and was published in the Journal of Allergy and Clinical Immunology.

Visit JACI using the link to read the original article.

• Amlitelimab
• atopic dermatitis
• clinical trial
• eczema
• lay summary
• OX40 ligand
• plain language summary